医药生物行业整体业绩保持稳健，科创医药指数ETF(588700)近4天获得连续资金净流入

Group 1 - The Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index increased by 0.22% as of May 8, 2025, with notable gains from stocks such as Borui Pharmaceutical (+6.22%) and Maiwei Biotech (+3.68%) [1] - The Sci-Tech Pharmaceutical Index ETF (588700) rose by 0.42%, and over the past month, it has accumulated a 9.37% increase, ranking first among comparable funds [1] - The trading volume for the Sci-Tech Pharmaceutical Index ETF was 10.82 million CNY, with a turnover rate of 3.98% [3] Group 2 - The Sci-Tech Pharmaceutical Index ETF saw a significant growth in scale, increasing by 22.06 million CNY over the past two weeks, and its shares grew by 22.50 million [3] - The ETF experienced continuous net inflows over four days, with a peak single-day net inflow of 9.73 million CNY, totaling 26.61 million CNY [3] - As of April 30, 2025, the top ten weighted stocks in the index accounted for 53.3% of the total, including companies like United Imaging Healthcare and BeiGene [3] Group 3 - The biopharmaceutical industry maintained stable performance in Q1 2025, with 368 out of 371 listed companies reporting a total revenue of 280.68 billion CNY, a year-on-year decrease of 9.18%, and a net profit of 37.84 billion CNY [3] - The focus for investment in the pharmaceutical sector remains on innovative drug development, with an emphasis on leading companies in overseas markets and those combining innovative and generic drugs [3] - Investors without stock accounts can access the Sci-Tech Biopharmaceutical ETF linked fund (021061) for exposure to the sector [4]